Hims & Hers (HIMS) Surges 12% to $30.95 on GLP-1 Tailwinds

Shares of Hims & Hers opened the session at $27.60 and climbed steadily throughout regular trading hours, reaching an intraday high near $30.99 before settling around $30.95 — a gain of roughly 12.15% on the day. The move was broadly consistent with sustained buying pressure, with the stock pushing through the $30 level in the first half of the session and holding above it for the remainder of the day.

The rally reflects continued investor appetite for companies tied to the GLP-1 weight-loss boom, particularly on the telehealth side where Hims & Hers competes. Rather than manufacturing the drugs themselves, telehealth platforms serve as a prescribing and distribution layer for patients seeking access to GLP-1 treatments, and that positioning has kept buyer interest elevated.

A gain of this magnitude heading into the next earnings report will draw attention. Analysts and traders will be watching whether the company's underlying revenue and subscriber trends can justify the elevated price, or whether the stock runs ahead of the fundamentals the next quarterly report will reveal.